Company intelligence / Profile preview

STC Life

South Korea

Ownership: Private
Development stage: Other

Overview

STC Life claims to have developed the world's first pluripotent stem cell without side effects (STC-nEPS), holding over 58 associated patents, and focuses on therapies targeting aging, incurable diseases, and specific cancers. Collaborations include Fraunhofer Institute and preclinical studies in multiple indications, but no reported clinical trial data.

Therapeutic areas: Rare DiseasesGastroenterologyOtherOncologyNeurology
Modalities: Stem cell therapyGene therapy
Industry: Biotech

Drug pipeline

2 assets

p62 gene therapy

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Fraunhofer Institute

Beyond the preview

Go deeper on STC Life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC Life.

Explore the full profile